Gyre Therapeutics (GYRE) Tax Provisions (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Tax Provisions of $621000.0 for Q1 2026, down 31.08% year-over-year from $901000.0 in Q1 2025, and up 377.23% quarter-over-quarter from -$224000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Tax Provisions (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Tax Provisions for 8 consecutive years, with $621000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions fell 31.08% year-over-year to $621000.0; the TTM figure through Mar 2026 stood at $2.8 million (down 25.12% YoY), while the FY2025 annual figure was $3.0 million, down 43.01% from the prior year.
- Tax Provisions rose to $621000.0 in Q1 2026 per GYRE's latest filing, from -$224000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $6.0 million in Q4 2022 and bottomed at -$224000.0 in Q4 2025.
- Historically, Tax Provisions has averaged $1.7 million across 5 years, with a median of $1.3 million in 2024.
- On a YoY basis, Tax Provisions climbed as much as 57.64% in 2025 and fell as far as 210.34% in 2025.
- Gyre Therapeutics' Tax Provisions stood at $6.0 million in 2022, then tumbled by 88.33% to $699000.0 in 2023, then sank by 70.96% to $203000.0 in 2024, then slumped by 210.34% to -$224000.0 in 2025, then jumped by 377.23% to $621000.0 in 2026.
- Business Quant data shows GYRE's Tax Provisions at $621000.0 in Q1 2026, -$224000.0 in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -164,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -164,000.00 |
| Mar 31, 2026 | 621,000.00 |
| Dec 31, 2025 | -224,000.00 |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 662,000.00 |
| Mar 31, 2025 | 901,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 2.55 Mn |
| Dec 31, 2023 | 699,000.00 |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 2.05 Mn |
| Dec 31, 2022 | 5.99 Mn |
| Mar 31, 2015 | 21,000.00 |
| Dec 31, 2014 | -56,000.00 |
| Sep 30, 2014 | 11,000.00 |
| Jun 30, 2014 | 45,000.00 |
| Mar 31, 2014 | 3.41 Mn |